Last10K.com

Agile Therapeutics Inc (AGRX) SEC Filing 8-K Material Event for the period ending Wednesday, October 24, 2018

Agile Therapeutics Inc

HISTORY TOOLS
CIK: 1261249 Ticker: AGRX

View differences made from one to another to evaluate Agile Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Agile Therapeutics Inc.

Continue

Assess how Agile Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Agile Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Agile Therapeutics Inc provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Exhibit 99.2: Additional Exhibits
Exhibit 99.3: Additional Exhibits
Ticker: AGRX
CIK: 1261249
Form Type: 8-K Corporate News
Accession Number: 0001104659-18-063591
Submitted to the SEC: Wed Oct 24 2018 8:13:30 AM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Wednesday, October 24, 2018
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/agrx/0001104659-18-063591.htm